Practical Guide for the Treatment of Leishmaniasis

[1]  S. Croft,et al.  Pharmacokinetics of Antimony in Patients Treated with Sodium Stibogluconate for Cutaneous Leishmaniasis , 2004, Pharmaceutical Research.

[2]  S. Sundar,et al.  A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate. , 1998, The American journal of tropical medicine and hygiene.

[3]  P. Olliaro,et al.  Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. , 1998, BMJ.

[4]  S. Reed,et al.  Rapid accurate field diagnosis of Indian visceral leishmaniasis , 1998, The Lancet.

[5]  J. Soto,et al.  Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  S. Sundar,et al.  Response to interferon-γ plus pentavalent antimony in Indian visceral leishmaniasis , 1997 .

[7]  O. Velasco-Castrejón,et al.  Treatment of cutaneous leishmaniasis with localized current field (radio frequency) in Tabasco, Mexico. , 1997, The American journal of tropical medicine and hygiene.

[8]  J. Berman,et al.  Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  R. Davidson.  AIDS and leishmaniasis. , 1997, Genitourinary medicine.

[10]  S. Sundar,et al.  Short-Course, Low-Dose Amphotericin B Lipid Complex Therapy for Visceral Leishmaniasis Unresponsive to Antimony , 1997, Annals of Internal Medicine.

[11]  J. Berman.  Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  S. Sundar,et al.  Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis. , 1997, The Journal of infectious diseases.

[13]  C. P. Thakur,et al.  Amphotericin B is superior to sodium antimony gluconate in the treatment of Indian post-kala-azar dermal leishmaniasis. , 1997, Annals of tropical medicine and parasitology.

[14]  P. Marsden,et al.  Mucosal leishmaniasis unresponsive to glucantime therapy successfully treated with AmBisome. , 1997, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[15]  J Dogra,et al.  Itraconazole and leishmaniasis: a randomised double-blind trial in cutaneous disease. , 1996, International journal for parasitology.

[16]  C. Bogdan,et al.  Invasion, control and persistence of Leishmania parasites. , 1996, Current opinion in immunology.

[17]  M. Gramiccia,et al.  Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  M. Gramiccia,et al.  Epidemiological surveillance of leishmaniasis in HIV‐1‐infected individuals in Italy , 1996, AIDS.

[19]  C. P. Thakur,et al.  Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study. , 1996, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[20]  C. P. Thakur,et al.  Comparison of regimens of amphotericin B deoxycholate in kala-azar. , 1996, The Indian journal of medical research.

[21]  R. Davidson,et al.  Pancreatic necrosis following treatment of leishmaniasis with sodium stibogluconate. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  J. Dórea,et al.  Antimony oxidation states in antileishmanial drugs. , 1995, The American journal of tropical medicine and hygiene.

[23]  S. Reed,et al.  Recombinant human granulocyte-macrophage colony-stimulating factor reverses neutropenia and reduces secondary infections in visceral leishmaniasis. , 1994, The Journal of infectious diseases.

[24]  G. Sutherland,et al.  Cardiac effects of sodium stibogluconate: myocardial, electrophysiological and biochemical studies. , 1994, QJM : monthly journal of the Association of Physicians.

[25]  A. Curry,et al.  Leishmaniasis of the tongue treated with liposomal amphotericin B. , 1994, The Journal of infection.

[26]  R. Janknegt,et al.  Clinical use of liposomal and lipid-complexed amphotericin B. , 1994, The Journal of antimicrobial chemotherapy.

[27]  J. Berman,et al.  Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  M. Grogl,et al.  Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm. , 1993, The New England journal of medicine.

[29]  P. D. Raadt,et al.  The burden of tropical diseases , 1993, The Medical journal of Australia.

[30]  M. Gramiccia,et al.  Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment. , 1992, Annals of tropical medicine and parasitology.

[31]  J. Berman,et al.  Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. , 1992, The American journal of tropical medicine and hygiene.

[32]  B. Arana,et al.  Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. , 1992, The Journal of infectious diseases.

[33]  C. P. Thakur,et al.  Observations on the effect of verapamil with sodium stibogluconate in kala azar. , 1992, Tropical and geographical medicine.

[34]  L. Schnur.  Control of the leishmaniases. Report of a WHO Expert Committee. , 1992, World Health Organization technical report series.

[35]  R. Neal,et al.  Reversal of drug resistance in Trypanosoma cruzi and Leishmania donovani by verapamil. , 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[36]  J. Berman,et al.  Biochemistry of Pentostam resistant Leishmania. , 1989, The American journal of tropical medicine and hygiene.

[37]  D. Smith,et al.  Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate. , 1988, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[38]  A. Bryceson,et al.  Therapy in man. , 1987 .

[39]  R. Killick-Kendrick,et al.  The Leishmaniases in biology and medicine , 1987 .